{"id":"topical-tacrolimus","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Application site burning or stinging"},{"rate":"5-20","effect":"Pruritus"},{"rate":"5-15","effect":"Skin irritation"},{"rate":"1-5","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that blocks T-cell proliferation and cytokine production when applied topically. By reducing local inflammatory immune responses without systemic immunosuppression, it alleviates inflammatory skin conditions. The drug is particularly useful for atopic dermatitis and other eczematous conditions where T-cell-mediated inflammation is pathogenic.","oneSentence":"Topical tacrolimus suppresses local immune responses by inhibiting calcineurin and T-cell activation in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:19.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (eczema)"},{"name":"Allergic contact dermatitis"},{"name":"Vitiligo"}]},"trialDetails":[{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT06638879","phase":"PHASE1","title":"Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-09-17","conditions":"Chronic Graft Versus Host Disease Oral","enrollment":7},{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT06362005","phase":"PHASE4","title":"The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-05-01","conditions":"Lichen Planus, Oral","enrollment":50},{"nctId":"NCT07239128","phase":"EARLY_PHASE1","title":"Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus","status":"COMPLETED","sponsor":"University of Seville","startDate":"2024-05-01","conditions":"Dry Eye Disease (DED)","enrollment":160},{"nctId":"NCT06880042","phase":"EARLY_PHASE1","title":"COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO","status":"ENROLLING_BY_INVITATION","sponsor":"Dr ayesha wahid","startDate":"2025-05-01","conditions":"Vitiligo - Macular Depigmentation, Tacrolimus","enrollment":60},{"nctId":"NCT05706636","phase":"NA","title":"T Central Memory Cells in Early Localized Non-Segmental Vitiligo","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-02-01","conditions":"Vitiligo","enrollment":22},{"nctId":"NCT05607901","phase":"PHASE2","title":"A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-28","conditions":"Dermatologic Disease","enrollment":100},{"nctId":"NCT06719024","phase":"PHASE2, PHASE3","title":"Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus","status":"RECRUITING","sponsor":"Hospital Authority, Hong Kong","startDate":"2024-11-29","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT06306274","phase":"PHASE2, PHASE3","title":"Topical Tacrolimus for Breast Cancer-related Lymphedema","status":"ENROLLING_BY_INVITATION","sponsor":"Odense University Hospital","startDate":"2024-09-09","conditions":"Lymphedema","enrollment":80},{"nctId":"NCT06203470","phase":"PHASE4","title":"Botox Versus Tacrolimus in Psoriasis Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-06","conditions":"Psoriasis Vulgaris","enrollment":60},{"nctId":"NCT04056962","phase":"PHASE2","title":"Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2019-09-01","conditions":"Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma","enrollment":50},{"nctId":"NCT06348602","phase":"PHASE1, PHASE2","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-08-01","conditions":"Ocular Graft-versus-host Disease","enrollment":60},{"nctId":"NCT05324618","phase":"PHASE4","title":"Tacrolimus Versus Hydrocortisone in Atopic Dermatitis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-05-15","conditions":"Atopic, Dermatitis","enrollment":200},{"nctId":"NCT05885269","phase":"PHASE1","title":"Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2022-11-01","conditions":"Alopecia Areata","enrollment":70},{"nctId":"NCT01082393","phase":"PHASE4","title":"Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-02-16","conditions":"Vitiligo","enrollment":14},{"nctId":"NCT03645057","phase":"PHASE3","title":"ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-20","conditions":"Atopic Dermatitis","enrollment":92},{"nctId":"NCT05577637","phase":"PHASE1","title":"Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2021-05-01","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT03673527","phase":"PHASE1","title":"Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-11-22","conditions":"Healthy","enrollment":24},{"nctId":"NCT04541290","phase":"PHASE1, PHASE2","title":"Tacrolimus as Treatment of Breast Cancer-Related Lymphedema","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2020-09-22","conditions":"Breast Cancer Lymphedema","enrollment":20},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT05139667","phase":"PHASE4","title":"Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-05-20","conditions":"Oral Lichen Planus","enrollment":30},{"nctId":"NCT05011916","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-08-10","conditions":"Corneal Neovascularization","enrollment":60},{"nctId":"NCT04114097","phase":"PHASE4","title":"The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover","status":"COMPLETED","sponsor":"Jacob Thyssen","startDate":"2019-08-22","conditions":"Atopic Dermatitis, Atopic Eczema","enrollment":36},{"nctId":"NCT04765826","phase":"NA","title":"Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-01-25","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT04718311","phase":"NA","title":"Study on Treatment for Patients With Symptomatic Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Catania","startDate":"2019-01-02","conditions":"Lichen Planus, Oral","enrollment":60},{"nctId":"NCT04705584","phase":"NA","title":"Topical Immuonosuppressant Drugs in Spring Catarrh","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-01","conditions":"Vernal Keratoconjunctivitis","enrollment":180},{"nctId":"NCT04147390","phase":"PHASE2, PHASE3","title":"Immunosuppression After Repeat Keratoplasty","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2019-11","conditions":"Keratopathy","enrollment":58},{"nctId":"NCT03865888","phase":"PHASE3","title":"Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome","status":"COMPLETED","sponsor":"Pavly Moawd","startDate":"2018-10-30","conditions":"Dry Eye, Sjogren Syndrome","enrollment":60},{"nctId":"NCT00762658","phase":"PHASE1","title":"A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11-30","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT03747614","phase":"PHASE4","title":"Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2017-06-30","conditions":"Dry Eye Syndromes, Inflammation, Microvessels","enrollment":20},{"nctId":"NCT03715387","phase":"PHASE2, PHASE3","title":"Tacrolimus for Malar Edema","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2018-10-10","conditions":"Edema Face","enrollment":100},{"nctId":"NCT03535051","phase":"NA","title":"Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2015-01-01","conditions":"Stable Vitiligo","enrollment":27},{"nctId":"NCT03199664","phase":"PHASE4","title":"Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2017-09-01","conditions":"Vitiligo","enrollment":100},{"nctId":"NCT00654355","phase":"PHASE4","title":"Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2008-04","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT02680717","phase":"PHASE1","title":"Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-03","conditions":"Scleroderma","enrollment":""},{"nctId":"NCT03464435","phase":"PHASE4","title":"A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-11-01","conditions":"Vernal Keratoconjunctivitis","enrollment":20},{"nctId":"NCT03365141","phase":"NA","title":"Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2017-11-14","conditions":"Vitiligo, Treatment, Intralesional Injection","enrollment":12},{"nctId":"NCT03358082","phase":"PHASE1, PHASE2","title":"Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2017-10-01","conditions":"Vitiligo, Tacrolimus","enrollment":100},{"nctId":"NCT00514982","phase":"PHASE2","title":"Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-08-07","conditions":"Hermanski-Pudlak Syndrome, Colitis, Cytokines","enrollment":""},{"nctId":"NCT00079183","phase":"PHASE2","title":"Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2002-04","conditions":"Graft Versus Host Disease","enrollment":44},{"nctId":"NCT01977781","phase":"PHASE1","title":"Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2013-12","conditions":"Ocular GVHD","enrollment":40},{"nctId":"NCT03047733","phase":"NA","title":"Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2015-07-21","conditions":"Dermatologic Disease, Vitiligo","enrollment":12},{"nctId":"NCT02794610","phase":"NA","title":"Ocular Penetration of Topical Tacrolimus Eye Drops","status":"UNKNOWN","sponsor":"The Eye Center and The Eye Foundation for Research in Ophthalmology","startDate":"2016-05","conditions":"Ocular Penetration of Topical Tacrolimus","enrollment":10},{"nctId":"NCT02744378","phase":"PHASE2","title":"Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Peradeniya","startDate":"2014-06","conditions":"Oral Lichen Planus","enrollment":68},{"nctId":"NCT02456025","phase":"PHASE4","title":"Topical Tacrolimus in Vernal Keratoconjunctivitis","status":"UNKNOWN","sponsor":"The Eye Center and The Eye Foundation for Research in Ophthalmology","startDate":"2013-04","conditions":"Vernal Keratoconjunctivitis","enrollment":20},{"nctId":"NCT00757874","phase":"PHASE2","title":"Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Deana Funaro","startDate":"2006-04","conditions":"Vulvar Lichen Sclerosus","enrollment":56},{"nctId":"NCT01544842","phase":"NA","title":"Tacrolimus Ointment in Oral Lichen Planus","status":"TERMINATED","sponsor":"University of Oulu","startDate":"2004-08","conditions":"Oral Lichen Planus","enrollment":28},{"nctId":"NCT01139450","phase":"PHASE3","title":"Study of 0417 Ointment in the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2008-01","conditions":"Atopic Dermatitis","enrollment":899},{"nctId":"NCT01053247","phase":"PHASE3","title":"Study of 0416 Ointment in the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2008-01","conditions":"Atopic Dermatitis","enrollment":793},{"nctId":"NCT00480896","phase":"PHASE3","title":"Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Dermatitis, Atopic","enrollment":250},{"nctId":"NCT00667056","phase":"PHASE4","title":"Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-07","conditions":"Dermatitis","enrollment":98},{"nctId":"NCT00560378","phase":"PHASE3","title":"Long-term Safety of Protopic in Atopic Eczema","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"1998-06","conditions":"Dermatitis, Atopic, Eczema, Atopic","enrollment":789},{"nctId":"NCT00666159","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00666302","phase":"PHASE4","title":"A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-10","conditions":"Dermatitis, Atopic","enrollment":413},{"nctId":"NCT00667160","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":426},{"nctId":"NCT00480610","phase":"PHASE3","title":"Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-04","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00801957","phase":"PHASE2","title":"Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-03","conditions":"Atopic Dermatitis","enrollment":260},{"nctId":"NCT00106496","phase":"PHASE4","title":"A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-10","conditions":"Dermatitis, Atopic","enrollment":410},{"nctId":"NCT01841008","phase":"PHASE2, PHASE3","title":"Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-12","conditions":"Pigmentation Disorders, Vitiligo","enrollment":35},{"nctId":"NCT00690105","phase":"PHASE4","title":"Protopic Ointment in Adult Atopic Eczema of the Face","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-02","conditions":"Dermatitis, Atopic","enrollment":577},{"nctId":"NCT00560326","phase":"PHASE2","title":"Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-06","conditions":"Dermatitis, Atopic","enrollment":50},{"nctId":"NCT00689832","phase":"PHASE4","title":"Protopic Ointment in Children Atopic Eczema","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-02","conditions":"Dermatitis, Atopic","enrollment":487},{"nctId":"NCT00686855","phase":"PHASE2","title":"Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-08","conditions":"Oral Chronic Graft-versus-host Disease","enrollment":46},{"nctId":"NCT00833079","phase":"PHASE1","title":"Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-10","conditions":"Atopic Dermatitis","enrollment":500},{"nctId":"NCT01702181","phase":"PHASE1","title":"A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-08","conditions":"Atopic Dermatitis","enrollment":92},{"nctId":"NCT01388517","phase":"PHASE4","title":"Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2008-01","conditions":"Pityriasis Alba","enrollment":39},{"nctId":"NCT01320579","phase":"PHASE2","title":"Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"BioCis Pharma Ltd","startDate":"2011-03","conditions":"Atopic Dermatitis","enrollment":159},{"nctId":"NCT01233570","phase":"PHASE2","title":"Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"","conditions":"Crohn Disease","enrollment":20},{"nctId":"NCT00236171","phase":"NA","title":"Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2004-09","conditions":"Psoriasis Vulgaris","enrollment":14},{"nctId":"NCT00779792","phase":"PHASE4","title":"Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2008-09","conditions":"Dermatitis, Contact, Dermatitis, Occupational","enrollment":36},{"nctId":"NCT00134394","phase":"PHASE2","title":"Etanercept With Tacrolimus for Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-02","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT00234728","phase":"NA","title":"Study of a New Dressing for Use With Topical Medications","status":"COMPLETED","sponsor":"Teikoku Pharma USA, Inc.","startDate":"2005-09","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT00317681","phase":"PHASE2","title":"Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2005-08","conditions":"Cutaneous Lupus Erythematosus","enrollment":30},{"nctId":"NCT00463723","phase":"PHASE2, PHASE3","title":"Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty","status":"TERMINATED","sponsor":"University Hospital Freiburg","startDate":"","conditions":"Penetrating Keratoplasty","enrollment":""},{"nctId":"NCT00443105","phase":"PHASE2","title":"Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"","conditions":"Allergic Conjunctivitis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1092,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tacrolimus eye drops"],"phase":"marketed","status":"active","brandName":"Topical tacrolimus","genericName":"Topical tacrolimus","companyName":"The Catholic University of Korea","companyId":"the-catholic-university-of-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical tacrolimus suppresses local immune responses by inhibiting calcineurin and T-cell activation in the skin. Used for Atopic dermatitis (eczema), Allergic contact dermatitis, Vitiligo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}